BioNTech SE
BNTX
$89.27
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.06B | 1.78B | 295.99M | 192.37M | 1.27B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.06B | 1.78B | 295.99M | 192.37M | 1.27B |
| Cost of Revenue | 352.49M | 173.38M | 86.71M | 88.19M | 259.56M |
| Gross Profit | 703.81M | 1.60B | 209.28M | 104.18M | 1.01B |
| SG&A Expenses | 253.66M | 173.61M | 155.94M | 126.91M | 140.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 214.08M | 807.04M | -28.83M | -55.56M | 47.01M |
| Total Operating Expenses | 1.41B | 1.81B | 791.61M | 712.65M | 1.10B |
| Operating Income | -352.26M | -38.58M | -495.62M | -520.28M | 168.96M |
| Income Before Tax | -264.72M | 28.88M | -457.04M | -468.71M | 321.07M |
| Income Tax Expenses | 90.33M | 62.43M | -18.27M | -31.15M | 44.45M |
| Earnings from Continuing Operations | -355.05M | -33.55M | -438.76M | -437.57M | 276.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -355.05M | -33.55M | -438.76M | -437.57M | 276.62M |
| EBIT | -352.26M | -38.58M | -495.62M | -520.28M | 168.96M |
| EBITDA | -310.76M | 106.62M | -437.74M | -475.24M | 296.66M |
| EPS Basic | -1.45 | -0.14 | -1.82 | -1.82 | 1.15 |
| Normalized Basic EPS | -0.62 | 0.12 | -1.11 | -1.15 | 0.92 |
| EPS Diluted | -1.45 | -0.14 | -1.82 | -1.82 | 1.15 |
| Normalized Diluted EPS | -0.62 | 0.12 | -1.11 | -1.15 | 0.92 |
| Average Basic Shares Outstanding | 244.20M | 239.17M | 241.63M | 240.35M | 240.28M |
| Average Diluted Shares Outstanding | 244.20M | 239.17M | 241.63M | 240.35M | 240.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |